HighTower Advisors’s Champions Oncology CSBR Stock Holding History
Bought
Maintained
Sold
Other funds holding CSBR
BMC
NMC
TAM
MBAM
HighTower Advisors's CSBR Position: Q2 2026 in Review
HighTower Advisors increased its Champions Oncology (CSBR) stake by 19% in Q2 2026, buying an estimated $40.6K and bringing the position to 41,901 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #3335.
HighTower Advisors first reported a position in CSBR in Q4 2019 and has held it in 27 quarters since. The position peaked at $337K in Q4 2024. 28 funds tracked by Wall St. Rank hold CSBR as of Q2 2026.
- HighTower Advisors held 41,901 shares of Champions Oncology worth $258K as of Q2 2026.
- HighTower Advisors bought 6,743 Champions Oncology shares in Q2 2026, an estimated $40.6K.
- Champions Oncology made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3335 holding.
- HighTower Advisors first reported a position in Champions Oncology in Q4 2019 and has held it in 27 quarters since.
- HighTower Advisors's Champions Oncology position peaked at $337K in Q4 2024.
- 28 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2026.
Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.